Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
Minchinton
A I
AI
Stanford University Medical Center, Division of Radiation Biology, Stanford University, CA 94305-5105.
Brown
J M
JM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D000860:Hypoxia; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D014227:Triazines; D000077704:Tirapazamine